We report a case of iatrogenic Creutzfeldt-Jakob disease (iCJD) after a 48.3-year incubation period in a patient treated with cadaveric human growth hormone. iCJD was pathologically confirmed; genetic analysis was negative for pathogenic mutations. Clinicians should consider iCJD in patients with progressive neurologic signs who had received cadaveric human growth hormone treatment.
Keywords: CJD; Creutzfeldt-Jakob disease; PrPSc proteins; United States; human growth hormone; myoclonus; prions and related diseases; sporadic.